
|Videos|July 2, 2013
Episode 2 - Elucidating the Patient's Starting Point in Care
Advertisement
Episodes in this series

The clinical paradigm for multiple sclerosis (MS) has witnessed an important shift in recent years, and those dynamics can be attributed to the advent of disease-modifying therapies (DMTs), increased awareness, and the conceptual evolution of MS becoming a treatable disease that requires early and effective intervention to better control the damage process caused by MS. Admittedly, while more patients with MS may be entering the health system through specialist referrals and neurologists, improved diagnostic modalities, such as the advances in neurology and neuro-imaging via MRI scan, arguably still does not explain the increased incidence of MS, and unfortunately, diagnosis of the disease is still not occurring early enough.
Advertisement
Related to this article

Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.

Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine event in San Francisco.

CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.

AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
3
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
4
Proposed Medicare Rate Cuts Draw AASM Opposition Ahead of Final Rule
5

















